 The FDA has now approved a new Alzheimer's treatment called Denanamab. It looks to be effective at slowing the decline of patients at early stages of the disease after as little as six months of infusions from the drug. Eli Lilly says the treatment, which they have branded as Kasunla, has a list price that adds up to some $32,000 if it is taken for a year. Medicare has said it will cover Kasunla similar to previous drugs in this class. That's CBS reporter Alexander Tinn.